4 unknown, 3 not yet recruiting, 3 recruiting, 2 completed. 12 Phase 1, 9 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 12 | Unknown 4, Not yet recruiting 3, Recruiting 3, Completed 2 |
| Phase 2 | 9 | Unknown 4, Not yet recruiting 2, Recruiting 2, Completed 1 |
Follow Efficacy: new trials by email Literature Review of Efficacy trials Research Report on Efficacy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 1/2 Clinical Study of HY07121 for Injection (Subcutaneous) in Patients With Advanced Solid Tumors Test Product HY07121 for Injection (Subcutaneous) - Safety, Tolerability | Phase 1 / Phase 2 | Not yet recruiting | Sichuan Huiyu Pharmaceutical Co., Ltd | 254 | 2026-09-08 | 2026-08-27 |
| Evaluation of the Efficacy and Safety of Megestrol Acetate in Preventing Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy Low dose of Megestrol Acetate Oral Suspension combined with standard therapy, Medium dose of Megestrol Acetate Oral Suspension combined with standard therapy, High dose of Megestrol Acetate Oral Suspension combined with standard therapy - Efficacy, Safety | Phase 1 | Not yet recruiting | Changchun GeneScience Pharmaceutical Co., Ltd. | 132 | 2025-09-29 | 2025-08-19 |
| Safety and Early Efficacy of iPSC-Derived Motor Neuron Progenitor Cells (XS228) in Subacute Spinal Cord Injury: A Phase I Trial Allogeneic Human Induced Pluripotent Stem Cell (iPSC)-Derived Motor Neuron Progenitor Cells - Spinal Cord Injury, Safety | Phase 1 | Recruiting | XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd. | 12 | 2025-07-02 | 2025-11-25 |
| Phase 1/2 Clinical Study of HY07121 Powder for Solution for Infusion in Patients With Advanced Solid Tumors Test Product HY07121 - Safety, Tolerability | Phase 1 / Phase 2 | Recruiting | Sichuan Huiyu Pharmaceutical Co., Ltd | 258 | 2024-10-24 | 2026-10-13 |
| AK112 Plus Platinum-based Chemotherapy for EGFR/ALK/ROS1 Positve NSCLC PD-1/VEGR bispecific antibodies (AK112) plus Platinum-based Chemotherapy - Efficacy | Phase 1 / Phase 2 | Not yet recruiting | Hunan Province Tumor Hospital | 150 | 2024-10-01 | 2024-10-09 |
| Phase 1/2 Study of HYP-2090PTSA in Patients With Advanced Solid Tumors Harboring KRAS Mutation Test product: HYP-2090PTSA - Safety, Tolerability | Phase 1 / Phase 2 | Recruiting | Sichuan Huiyu Pharmaceutical Co., Ltd | 257 | 2024-02-04 | 2026-01-29 |
| A Study of GC101 TIL in Advanced Melanoma (BZ) GC101 TIL - Tumor Infiltrating Lymphocytes, Safety | Phase 1 / Phase 2 | Completed | Shanghai Juncell Therapeutics | 18 | 2023-11-08 | 2025-12-23 |
| Stereotactic Body Radiotherapy Combined With Cadonilimab for Advanced Refractory Malignant Solid Tumors Cadonilimab, Stereotactic body radiotherapy - Advanced Solid Tumor, Stereotactic Body Radiotherapy | Phase 1 / Phase 2 | Unknown | Peking University Third Hospital | 60 | 2023-06-21 | 2023-06-23 |
| A Phase Ic/IIb Study to Evaluate the Efficacy，Safety and Pharmacokinetics of HST in Patients With CHB Hepenofovir Fumarate Tablets - Efficacy, Safety | Phase 1 / Phase 2 | Unknown | Xi'an Xintong Pharmaceutical Research Co.,Ltd. | 48 | 2022-11-10 | 2023-11-08 |
| A Phase I Study of GC101 TIL in Advanced Solid Tumors TIL therapy - Tumor Infiltrating Lymphocytes, Safety | Phase 1 | Completed | Shanghai Juncell Therapeutics | 43 | 2022-10-12 | 2025-12-10 |
| PD-L1 Inhibitor Rechallenge After PD-1 Immunotherapy for Patients With Solid Tumor Beyond Lung Cancer PD-L1 inhibitor - Efficacy, Safety | Phase 1 / Phase 2 | Unknown | The Affiliated Hospital of Qingdao University | 30 | 2022-04-01 | 2022-04-13 |
| Treatment of MB07133 Plus Sintilimab in Patients With Hepatocellular Carcinoma Sintilimab 200mg+MB07133 600mg - Safety Issues, Efficacy | Phase 1 / Phase 2 | Unknown | Xi'an Xintong Pharmaceutical Research Co.,Ltd. | 39 | 2022-01-18 | 2023-11-21 |
Drug-Related Side Effects and Adverse Reactions (2) · Diabetes Mellitus, Insulin-Dependent, 12 (1) · Melanoma (1) · Parkinson Disease 4, Autosomal Dominant Lewy Body (1) · Spinal Cord Injuries (1)
Chemically-Induced Disorders (2) · Central Nervous System Diseases (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms by Site (1) · Neoplasms, Germ Cell and Embryonal (1) · Neoplasms, Nerve Tissue (1) · Nervous System Diseases (1) · Neuroectodermal Tumors (1) · Neuroendocrine Tumors (1) · Nevi and Melanomas (1) · Skin Diseases (1) · Skin Neoplasms (1) · Skin and Connective Tissue Diseases (1) · Spinal Cord Diseases (1)
4-amino-1-(5-O-(2-oxo-4-(4-pyridyl)-1,3,2-dioxaphosphorinan-2-yl)arabinofuranosyl)-2(1H)-pyrimidinone (1) · Immune Checkpoint Inhibitors (1) · Injections (1) · Injections, Subcutaneous (1) · Radiosurgery (1) · Standard of Care (1) · sintilimab (1)
Sichuan Huiyu Pharmaceutical Co., Ltd (3) · Shanghai Juncell Therapeutics (2) · Xi'an Xintong Pharmaceutical Research Co.,Ltd. (2) · Changchun GeneScience Pharmaceutical Co., Ltd. (1) · Hunan Province Tumor Hospital (1) · Peking University Third Hospital (1) · The Affiliated Hospital of Qingdao University (1) · XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd. (1)
China (9)
Hongqing Zhuang, M.D. (1) · Jun Guo (1) · Li Zhang, PHD (1) · Limin Rong, prof and M.D (1) · Xiaochun Zhang, Prof (1)